M E Kalaycio

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Your patient has chronic leukemia: Now what?
    Matt Kalaycio
    Chairman, Department of Hematology and Medical Oncology, and Staff, Transplantation Center and Department of Cancer Biology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA E mail
    Cleve Clin J Med 83:575-81. 2016
  2. doi request reprint BU- vs TBI-based conditioning for adult patients with ALL
    M Kalaycio
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44196, USA
    Bone Marrow Transplant 46:1413-7. 2011
  3. pmc Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial
    Xing Yue He
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio USA
    BMC Cancer 2:12. 2002
  4. ncbi request reprint Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia
    M Kalaycio
    Department of Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:753-8. 2007
  5. ncbi request reprint Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor
    M Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Clin Oncol 24:58-63. 2001
  6. ncbi request reprint CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens
    M Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 35:247-52. 2005
  7. ncbi request reprint High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant
    Matt Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Transplant 20:783-7. 2006
  8. doi request reprint Bendamustine: a new look at an old drug
    Matt Kalaycio
    Chronic Leukemia and Myeloma Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 115:473-9. 2009
  9. ncbi request reprint Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia
    Matt Kalaycio
    Department of Hematology, The Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH, USA
    J Clin Oncol 24:3604-10. 2006
  10. doi request reprint Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia
    Matt Kalaycio
    Department of Hematologic Malignancies and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Am J Hematol 83:831-4. 2008

Detail Information

Publications63

  1. doi request reprint Your patient has chronic leukemia: Now what?
    Matt Kalaycio
    Chairman, Department of Hematology and Medical Oncology, and Staff, Transplantation Center and Department of Cancer Biology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA E mail
    Cleve Clin J Med 83:575-81. 2016
    ..More patients are surviving cancer and therefore are increasingly being seen by primary care physicians, who must be aware of complications of standard and newer treatments and how to manage them. ..
  2. doi request reprint BU- vs TBI-based conditioning for adult patients with ALL
    M Kalaycio
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44196, USA
    Bone Marrow Transplant 46:1413-7. 2011
    ..08) in patients treated with TBI compared with those treated with BU. However, the advantage for TBI could not be confirmed by multivariable analysis where only disease status retained statistical significance...
  3. pmc Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial
    Xing Yue He
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio USA
    BMC Cancer 2:12. 2002
    ..We added G-CSF to EMA (EMA-G) for therapy of advanced high-risk AML patients...
  4. ncbi request reprint Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia
    M Kalaycio
    Department of Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:753-8. 2007
    ..70, 95% confidence interval 1.41-5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts...
  5. ncbi request reprint Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor
    M Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Clin Oncol 24:58-63. 2001
    ..Long-term survival, however, was poor and innovative treatment approaches to maintain remission are needed...
  6. ncbi request reprint CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens
    M Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 35:247-52. 2005
    ..Our results confirm that MUD BMT with CD8+ TCD for AML is a potentially curative treatment option...
  7. ncbi request reprint High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant
    Matt Kalaycio
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Transplant 20:783-7. 2006
    ..6%. Risk factors for pulmonary mortality included older age and lower baseline D(CO) and FEV1. We conclude that high-dose busulfan is associated with pulmonary mortality after autologous transplant, particularly in older patients...
  8. doi request reprint Bendamustine: a new look at an old drug
    Matt Kalaycio
    Chronic Leukemia and Myeloma Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 115:473-9. 2009
    ..Bendamustine is an active agent for the treatment of low-grade lymphoproliferative disorders and more study is needed to determine which dose and schedule is optimal, and which patients will derive the greatest benefit from its use...
  9. ncbi request reprint Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia
    Matt Kalaycio
    Department of Hematology, The Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH, USA
    J Clin Oncol 24:3604-10. 2006
    ..We reviewed our experience in 526 patients with lymphoma treated by ASCT to determine whether difficult stem-cell harvests predict for an increased risk of t-MDS/AML...
  10. doi request reprint Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia
    Matt Kalaycio
    Department of Hematologic Malignancies and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Am J Hematol 83:831-4. 2008
    ..Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches...
  11. ncbi request reprint Chronic myelogenous leukemia: the news you have and haven't heard
    M E Kalaycio
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:913, 917, 920-1, 925-6. 2001
    ..Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigms..
  12. pmc Allogeneic hematopoietic cell transplant for prolymphocytic leukemia
    Matt E Kalaycio
    Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:543-7. 2010
    ..Further study of a larger population of patients is needed to determine which patients are more likely to benefit...
  13. ncbi request reprint Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation
    S B Mossad
    Department of Infectious Diseases, Cleveland Clinic Foundation, 9500 Euclid Avenue S-32, Cleveland, OH 44195, USA
    Bone Marrow Transplant 28:491-5. 2001
    ..The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients...
  14. ncbi request reprint Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival
    R Dean
    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 36:1049-52. 2005
    ..Strategies to increase autograft DC content or accelerate DC recovery after autologous HSCT might improve outcomes in this setting...
  15. ncbi request reprint High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
    S S Farag
    Hematologic Malignancies Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Bone Marrow Transplant 35:653-61. 2005
    ..03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients...
  16. doi request reprint Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation
    S Fu
    Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Bone Marrow Transplant 50:1326-30. 2015
    ..More research is needed to understand the mechanisms of health-care disparities and interventions to mitigate them. ..
  17. ncbi request reprint Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies
    B J Bolwell
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:437-41. 2007
    ..We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown...
  18. ncbi request reprint Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia
    X Y He
    Department of Hematology and Medical Oncology, 9500 Euclid Avenue, R35, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Leukemia 17:1078-84. 2003
    ..It is efficacious for induction therapy for newly diagnosed de novo AML. A high CR rate can be achieved with only one course of this chemotherapy...
  19. ncbi request reprint A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation
    B J Bolwell
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 30:587-91. 2002
    ..Worsening mucositis correlated with a longer inpatient length of stay. We conclude that several variables contribute to worsening mucositis during autologous transplantation, including etoposide in the progenitor cell mobilizing regimen...
  20. doi request reprint Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation
    R M Sobecks
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 41:709-14. 2008
    ..Conversely, patients with greater inhibitory KIR scores may have less active NK cell and T-cell populations, which may make them more likely to achieve CDC...
  21. ncbi request reprint Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant
    B Bolwell
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 33:419-23. 2004
    ..001) and bad risk disease (P=0.009). We conclude that the platelet count 100 days post transplant is a powerful predictor of overall survival...
  22. doi request reprint Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?
    C Stotler
    Taussig Cancer Center, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 45:49-52. 2010
    ..Backup harvest is unnecessary for HLA well-matched myeloablative transplants, but may be useful in patients at higher risk of graft failure...
  23. ncbi request reprint Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies
    S R Fanning
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Br J Haematol 135:374-81. 2006
    ....
  24. doi request reprint A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
    E Copelan
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Bone Marrow Transplant 43:101-5. 2009
    ..There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation...
  25. ncbi request reprint Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
    S D Smith
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:239-43. 2007
    ..Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed...
  26. ncbi request reprint Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
    T Y Kang
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:973-8. 2007
    ..In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL...
  27. doi request reprint 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    R M Sobecks
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 42:715-22. 2008
    ..A dose of 400 cGy TBI administered with fludarabine is well tolerated and further study is needed to determine whether outcomes are superior to those with 200 cGy TBI...
  28. ncbi request reprint Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma
    B Bolwell
    Department of Hematology and Medical Oncology and Transplant Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Lymphoma 1:226-31; discussion 232-3. 2000
    ..We concluded that autologous PBPC transplantation is a viable and potentially effective treatment option for patients who have transformed diffuse large-cell lymphoma...
  29. ncbi request reprint Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection
    R K Avery
    Department of Infectious Disease, Cleveland Clinic Foundation, Desk S 32, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Bone Marrow Transplant 34:1071-5. 2004
    ..However, the toxicity profile of leflunomide in patients with underlying GVHD remains to be defined...
  30. ncbi request reprint A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
    B Bolwell
    Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 34:621-5. 2004
    ....
  31. ncbi request reprint Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course
    R Avery
    Bone Marrow Transplantation Program and the Departments of Hematology Oncology, Pharmacy, and Infectious Disease, Cleveland Clinic Foundation, OH 44195, USA
    Bone Marrow Transplant 35:497-9. 2005
    ..Early VRE may be a marker for the critical condition of these high-risk patients at the time of transplant...
  32. ncbi request reprint Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection
    S Mossad
    Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, USA
    Bone Marrow Transplant 35:375-81. 2005
    ..Hospital readmission rates were similar in both groups. Steroid prophylaxis significantly decreases the risk of ES following AHSCT, and is associated with shortened hospitalization, without increasing risk of infection...
  33. ncbi request reprint Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors
    R M Sobecks
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 39:417-24. 2007
    ..003). Since C1/C2 heterozygotes have a greater opportunity to engage inhibitory KIRs than do C1 or C2 homozygotes, they may more effectively inhibit KIR-positive NK- and T-cell populations involved in graft vs leukemia responses...
  34. ncbi request reprint Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer
    B Bolwell
    Department of Hematology and Medical Oncology, and Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Bone Marrow Transplant 27:843-6. 2001
    ..0001 and P = 0.004, respectively). We conclude that patients having a node ratio of < 0.7 have a significantly better prognosis following autologous PBPC transplantation than do patients with a ratio > or = 0.7...
  35. ncbi request reprint Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy
    M Kalaycio
    The Cleveland Clinic Foundation, Ohio 44195, USA
    J Cancer Res Clin Oncol 124:265-9. 1998
    ..A randomized controlled trial was designed to assess the relative efficacy and toxicity of granisetron compared to ondansetron in the setting of autologous stem cell transplantation...
  36. doi request reprint Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
    S D Smith
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 46:262-6. 2011
    ..Again, no differences in outcomes were observed. This suggests that auto-SCT may be equally effective in pts relapsing after first-line therapy including R, and should remain the standard of care for relapsed DLBCL...
  37. ncbi request reprint Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone
    B Bolwell
    Department of Hematology and Medical Oncology, Cleveland, OH, USA
    Bone Marrow Transplant 31:95-8. 2003
    ..2 vs 0.4, P<0.001). We conclude that the combination of chemotherapy plus G-CSF yields different mobilized dendritic cell subsets than does G-CSF alone...
  38. ncbi request reprint Influence of type of antecedent disorder on outcome of therapy-related AML
    S R Mohan
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Cleveland Clinic, Cleveland, OH
    J Clin Oncol 29:6628. 2011
    ..Metaphase cytogenetics (MC) at tAML diagnosis effect prognosis, but the influence of the type of antecedent disorder for which treatment was previously given is less clear...
  39. doi request reprint Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients
    B K Hamilton
    Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA
    Bone Marrow Transplant 50:1235-40. 2015
    ..QOL assessments, particularly physical functioning and functional well-being, may provide independent prognostic information beyond standard clinical measures in allogeneic HCT recipients. ..
  40. doi request reprint Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation
    T Radivoyevitch
    Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
    Leukemia 30:285-94. 2016
    ....
  41. doi request reprint Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis
    A Tabarroki
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Leukemia 28:1486-93. 2014
    ....
  42. ncbi request reprint The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization
    R K Avery
    Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 30:311-4. 2002
    ..We conclude that etoposide mobilization is associated with a significant incidence of neutropenic fever, which can be substantially reduced by a vigorous antimicrobial prophylactic program...
  43. ncbi request reprint Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction?
    W H W Tang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Kaufman Center for Heart Failure, Cleveland, OH, USA
    Bone Marrow Transplant 34:603-7. 2004
    ..As medical care for HF and ABMT improves, the exclusion criteria for ABMT with regard to HF and impaired LVEF should be re-examined...
  44. ncbi request reprint Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up
    B Bolwell
    Department of Hematology and Medical Oncology, Taussig Cancer Center, and Transplant Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R32, Cleveland, Ohio 44195, USA
    Bone Marrow Transplant 29:673-9. 2002
    ..We conclude that patients with NHL treated with ABMT, if in CR 5 years post transplant, are at very low risk of relapse with extended follow-up, suggesting the possibility of cure for all histologies, including those with low grade NHL...
  45. ncbi request reprint Syngeneic graft-versus-host disease: a report of two cases and literature review
    T Latif
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 32:535-9. 2003
    ..The current report reviews these cases and presents two additional cases of severe SGVHD that have occurred at our institution...
  46. pmc Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
    V Cheriyath
    Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Br J Cancer 104:957-67. 2011
    ..Therefore, we examined the potentiation of apoptosis and related mechanisms of HDACis and doxorubicin combination in a panel of myeloma cell lines and in 25 primary myelomas...
  47. doi request reprint Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
    Anjali S Advani
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:1560-6. 2008
    ..27, CI (1.04-1.55), p = 0.019] and decreased overall survival [HR 1.34, CI (1.08-1.67), p = 0.009]. Delayed time from IC to PRT (> or =6.6 weeks) was associated with a statistically worse progression-free and overall survival...
  48. ncbi request reprint A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
    Joseph Moore
    Duke University Medical Center, Morris Cancer Clinics, P O Box 3872, Durham, NC 27710, United States
    Leuk Res 30:777-83. 2006
    ..Serious adverse events for the oblimersen/GO combination were qualitatively similar to those reported for GO alone. Oblimersen can be safely combined with GO. Assessment of incremental benefit will require a randomized trial...
  49. ncbi request reprint Treatment of refractory and relapsed acute myelogenous leukemia
    Slobodan Stanisic
    Cleveland Clinic Foundation, Department of Hemotology and Medical Oncology, 9500 Euclid Ave R 35, Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 2:287-95. 2002
    ..New and novel agents are also undergoing trials in an attempt to improve on the overall poor outcomes...
  50. ncbi request reprint Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    J Clin Oncol 23:4110-6. 2005
    ..In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)...
  51. ncbi request reprint Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Navin Wadehra
    Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 12:1343-9. 2006
    ..This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality...
  52. ncbi request reprint The clinical picture. A woman with aplastic anemia and a rash
    Ila Tamaskar
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:1088-90. 2006
  53. ncbi request reprint The role of post-remission chemotherapy for older patients with acute myelogenous leukemia
    Rony M Abou-Jawde
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Leuk Lymphoma 47:689-95. 2006
    ..21 and P = 0.15, respectively). PRT has not clearly improved survival in older patients with AML, and therefore the routine addition of chemotherapy to older patients in complete remission is not indicated...
  54. ncbi request reprint Prolymphocytic leukemia
    Ahmed Absi
    Taussig Cancer Cancer, The Cleveland Clinic Foundation, 9500 Euclid Avenue R35, Cleveland OH 44195, USA
    Curr Treat Options Oncol 6:197-208. 2005
    ..Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder...
  55. ncbi request reprint Induction chemotherapy for acute myelogenous leukemia
    Matt Kalaycio
    Curr Hematol Rep 4:49-50. 2005
  56. ncbi request reprint Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 110:1752-9. 2007
    ..Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization time...
  57. ncbi request reprint Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML
    Anjali S Advani
    Taussig Cancer Center, Leukemia Program, The Cleveland Clinic CCF, Cleveland, OH 44195, USA
    Leuk Res 32:913-8. 2008
    ..Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials...
  58. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
    ..We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination...
  59. ncbi request reprint Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
    Sujith Kalmadi
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Cancer 107:136-40. 2006
    ..Epsilon aminocaproic acid (EACA) is an antifibrinolytic drug that has been used to control hemorrhage by stabilizing the thrombus. It has been used in thrombocytopenic patients largely on an empiric basis...
  60. pmc Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome
    Marcin W Wlodarski
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center R 40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
    Blood 108:2632-41. 2006
    ..We conclude that immunodominant clonotypes associated with marrow failure may be used to monitor immunosuppressive therapy...
  61. pmc High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes
    Ramon Tiu
    Experimental Hematology and Hematopoiesis Section, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Exp Hematol 35:240-51. 2007
    ..Therefore, it is likely that chromosomal defects in myelodysplastic syndromes may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods...
  62. doi request reprint Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit
    Snehal G Thakkar
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 112:2233-40. 2008
    ..Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US...
  63. ncbi request reprint Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia: a case series and review of the literature
    John Hill
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Hematol 75:134-8. 2004
    ..We conclude that laparoscopic splenectomy is a safe and effective treatment for autoimmune hemolytic anemia in patients with CLL who fail medical therapy...